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ABSTRACT
Doxorubicin (Dox) is known to cause cardiomyopathy and con-
gestive heart failure upon chronic administration. The mecha-
nisms underlying these toxicities remain uncertain but have
been attributed, at least in part, by induction of cardiac cell
apoptosis. Fas ligation with its cognate ligand (FasL) induces
apoptosis and activates cellular inflammatory responses asso-
ciated with tissue injury. We determined whether interruption of
Fas/FasL interaction by cardiac-targeted expression of soluble
Fas (sFas), a competitive inhibitor of FasL, would protect
against Dox chronic cardiotoxicity in mice. Wild-type (WT) and
sFas transgenic mice were administrated intravenously with 4
mg/kg Dox or with an equivalent volume of saline twice a week
for a total of 10 injections. There were 25% mortality in WT
mice, but no death was observed in sFas mice during the
period of Dox treatment. Echocardiographic evaluation re-
vealed a significant decrease in left ventricle fractional short-
ening after Dox treatment in WT mice but not in sFas mice. WT
mice treated with Dox developed extensive myocardial cyto-
plasmic vacuolization, apoptosis, and interstitial fibrosis, which
were much less or absent in sFas mice. The increased inducible
nitric oxide synthase expression, nitric oxide production, super-
oxide generation, and peroxynitrite formation after Dox treatment
in WT mice were attenuated by sFas expression. sFas expression
also attenuated Dox-mediated induction of proinflammatory cyto-
kines, tumor necrosis factor-, interleukin (IL)-1, and IL-6 in the
myocardium. These observations indicate that FasL is an impor-
tant mediator in Dox-associated cardiotoxicity by generating re-
active oxygen and nitrogen species.
Doxorubicin (Dox) is a widely used chemotherapeutic agent
in the treatment of a variety of cancers. However, the major
limitation of Dox in the clinical application is its dose-related
cardiotoxicity that may cause irreversible myocardial dam-
age, leading to dilated cardiomyopathy with congestive heart
failure (Singal and Iliskovic, 1998). Although the precise
mechanisms of Dox cardiotoxicity remain elusive, there is
increasing evidence that Dox exposure can trigger myocyte
apoptosis and that this type of cell death represents the
predominant form of myocyte damage seen in this setting
(Kalyanaraman et al., 2002; Takemura and Fujiwara, 2007).
Fas ligation with its cognate ligand (FasL) is one of the key
regulators of the apoptotic pathway and has been shown to
exist in the heart (Setsuta et al., 2004). Fas consists of two
isoforms, membrane-anchored Fas and soluble (sFas). The
membrane isoform (membrane-anchored Fas) is a 45-kDa
cell surface protein containing a single transmembrane re-
gion and induces apoptosis upon FasL binding, whereas the
soluble isoform (sFas) lacks the transmembrane domain be-
cause of alternative splicing of the transcript and is thought
to block Fas-mediated apoptosis by sequestering FasL (Suda
et al., 1993; Cheng et al., 1994). In experimental models, Fas
is overexpressed by cardiac myocytes in response to Dox
administration (Nakamura et al., 2000; Lien et al., 2006).
Both in vitro and in vivo studies demonstrated that blocking
of the Fas/FasL interaction with an FasL-neutralizing anti-
body inhibited Dox-induced toxicity in cardiomyocytes (Na-
kamura et al., 2000; Wu et al., 2002). In a recent study, an
elevated level of sFas has been found in patients with several
different cancers (Tamakoshi et al., 2008), and studies have
shown that patients with increased levels of sFas during
chemotherapy had a better overall survival (Perik et al.,
2006; Pichon et al., 2006). The recent reports from others and
our laboratory demonstrate that expression of sFas leads to
improvement in cardiac function and overall survival in mice
with ischemic myocardial injury (Li et al., 2004; Niu et al.,
2006). To investigate whether sFas has a beneficial effect on
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chronic Dox cardiotoxicity and elucidate possible underlying
mechanisms, transgenic mice with cardiac-targeted expres-
sion of sFas were administrated repeatedly with a low dose of
Dox over a period of 7 weeks. Data presented here demon-
strate that cardiac-targeted expression of sFas attenuates
Dox-induced generation of reactive oxygen and nitrogen spe-
cies, formation of peroxynitrite, apoptotic cell death, and
production of proinflammatory cytokines in the heart, lead-
ing to the inhibition of chronic Dox cardiotoxicity.
Materials and Methods
Animals. Transgenic mice with cardiac-targeted expression of
sFas were generated from the FVB/N strain under the control of
-myosin heavy-chain promoter, and the homozygous sFas trans-
genic mice were produced by interbreeding and maintained in our
animal facility. Detailed description for the development and char-
acterization of sFas mice were reported previously (Niu et al., 2006).
Wild-type (WT) mice from the same background (FVB/N strain) were
purchased from Harlan (Indianapolis, IN) and served as controls.
Male mice, 12 weeks old, were used for experiments. The experimen-
tal procedures in mice and protocol used in this study were approved
by Animal Care and Use Committee of the University of Central
Florida, in accordance with the Guide for the Care and Use of Lab-
oratory Animals (Institute of Laboratory Animal Resources, 1996).
Experimental Protocol. Both WT and sFas mice were randomly
assigned to two groups (saline and Dox; n  10–12 for each group)
and injected intravenously with 4 mg/kg Dox (Sigma-Aldrich, St.
Louis, MO) dissolved in sterile saline (Dox-treated groups) or with an
equivalent volume of pathogen-free saline only (saline-treated
groups) via tail vein twice a week for a total of 10 injections. After the
first four injections, the animals were not treated for 2 weeks to allow
the recovery of bone marrow depression. The dosage of Dox and
treatment protocol were based on the previous report that showed
the clinically relevant cardiomyopathy in the mouse (Sun et al.,
2001). The animals were kept in individual cages in temperature-
controlled rooms. They had free access to tap water and food during
the experimental period. The animals were observed daily and
weighed weekly throughout the duration of the study and were
euthanized under anesthesia after echocardiographic examination in
the 2 weeks after the last Dox injection.
Assessment of Cardiac Function. At the beginning of Dox
treatment and on the day that animals were euthanized, cardiac
function was assessed by echocardiography. In brief, mice were
lightly anesthetized via a nose cone and maintained with 0.5 to
2.0% isoflurane (AErrane; Baxter, McGaw Park, IL) mixed with
oxygen. The chest was shaved, and animals were placed in a supine
position with a slight tilt to the left decubitus position. Thermoreg-
ulation was achieved by using an autoregulated heating pad. A
15-MHz high-frequency transducer connected to an Agilent Technol-
ogies SONOS 4500 ultrasound machine (Philips Medical System;
Agilent Technologies, Santa Clara, CA) was used. A two-dimensional
short-axis view of the left ventricle was obtained at the level of the
papillary muscles, and two-dimensionally targeted M-mode tracings
were recorded at a sweep speed of 100 mm/s. The left ventricular
end-diastolic dimension (LVEDD) and left ventricular end-systolic
dimension were measured using online analyzing system to calculate
the left ventricular fractional shortening, an index of cardiac func-
tion, by the equation: fractional shortening  [(LVEDD  left ven-
tricular end-systolic dimension)/LVEDD] 100%. All measurements
were made according to the guidance of the American Society of
Echocardiography leading edge-to-leading edge technique. Data
from three to five consecutive selected cardiac cycles were analyzed
and averaged.
Cardiac Histology and Histomorphometric Analysis. After
echocardiographic measurements and collection of blood samples,
the hearts were removed, weighed, and fixed by immersion in 10%
phosphate-buffered formaldehyde or snap-frozen in liquid nitrogen
for further examination as described below. A few photographs of
whole hearts were taken with a Spot Insight digital camera (Diag-
nostic Instruments, Inc., Sterling Heights, MI) with a computerized
Nikon SMZ1000 dissecting microscope (Nikon, Tokyo, Japan). Equa-
torial regions of the heart were routinely processed and paraffin
embedded. Sections were stained with hematoxylin and eosin and
Masson’s trichrome using standard protocols for histomorphometric
analysis. Quantitative assessments for myocardial fibrotic area were
performed on five sections in five randomly selected fields per section
and expressed as interstitial collagen volume fraction. The collagen
volume fraction was calculated as a percentage of the sum of all
blue-stained areas to the total ventricular areas by using the Meta-
morph Series 6.2 image analysis program (Molecular Devices,
Sunnyvale, CA) as described previously (Niu et al., 2006).
Immunohistochemical Detection of Peroxynitrite Forma-
tion and Poly(ADP-Ribose) Polymerase Activation. Immuno-
histochemistry was performed in sections to determine expression
levels of 3-nitrotyrosine (3-NT; a biomarker of peroxynitrite forma-
tion and oxidative stress) and cleaved poly(ADP-ribose) polymerase
(PARP p85 fragment, a marker for detection of apoptosis) in the
myocardium. In brief, after deparaffinization and rehydration, sec-
tions (5 m) were treated with 3% H2O2/methanol solution to quench
endogenous peroxidase activity and incubated with blocking buffer
(PerkinElmer Life and Analytical Sciences, Waltham, MA) to block
nonspecific binding. Sections were then incubated with polyclonal
rabbit anti-nitrotyrosine (1:100; Millipore, Billerica, MA) and poly-
clonal rabbit anti-PARP p85 fragment (1:00; Promega, Madison, WI)
antibodies overnight at 4°C, respectively, followed by incubation
with horseradish peroxidase-conjugated goat anti-rabbit antibody
(1:200; Santa Cruz Biochemicals, Santa Cruz, CA). Peroxidase activ-
ity was visualized with diaminobenzidine. The counterstain was
developed with hematoxylin. Incubation without primary antibody
was performed as controls. On control sections, no specific immuno-
reactivity was detected. Photomicrographs were obtained at 400
magnification. The positive areas of staining were measured and
expressed as the percentage of total LV area by using the Metamorph
Series 6.2 image analysis program. The immunoreactivity for 3-NT
and PARP p85 fragment were quantified from five randomly selected
sections for each animal, and five animals were studied per group.
Measurement of Superoxide Generation in Hearts. Super-
oxide anion generation in response to phorbol 12-myristate 13-ace-
tate (PMA; Sigma-Aldrich) in freshly prepared ventricular homoge-
nates was assessed spectrophotometrically by luminol-mediated
chemiluminescence, as described previously (Iwata et al., 1995), with
the Superoxide Anion Detection Kit (Calbiochem, San Diego, CA)
according to the manufacturer’s instructions. PMA is an activator of
the intracellular enzyme protein C and is a potent stimulator of
NADPH oxidase. Luminol is sensitive to the presence of superoxide
anion and was used to monitor NADPH-stimulated superoxide gen-
eration. In brief, cardiac tissues were homogenized and centrifuged
at 1000g for 10 min. The supernatant (100 l) was added to 100 l of
the SuperoxideAnion assay medium reagent mixture containing 200
M luminol, 250 M enhancer, and 200 ng/ml PMA, then incubated
for 30 min at room temperature. Chemiluminescence was measured
with a spectrophotometer, and the background luminescence was
subtracted from the readings with PMA. Values were standardized
to the amount of protein present and expressed as relative light
intensity per milligram of protein.
Measurement of the ROS Generation in the Dox-Treated
H9c2 Cells. The redox-sensitive fluorophore hydroethidium has
been used to monitor the intracellular oxidative stress (Benov et al.,
1998). In brief, the H9c2 cardiomyocyte cell line (CRL-1446; Ameri-
can Type Culture Collection, Manassas, VA) was maintained in
Dulbecco’s modified Eagle’s medium containing 10% (v/v) heat-inac-
tivated fetal bovine serum, 100 U/ml penicillin G, 100 mg/ml strep-
tomycin, and 2 mM L-glutamine. After pretreatment of H9c2 with
sFas (hBA157, 10 g/ml; Santa Cruz Biochemicals) and then 2 M
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Dox for 6 h, culture medium was aspirated, and cells were washed
with Dulbecco’s phosphate-buffered saline and incubated in fresh
culture medium without fetal bovine serum. Hydroethidine (10 M)
was added to the cells and incubated for 30 min, during which
hydroethidine was oxidized to the fluorophore dihydro--erythroi-
dine (DHE). Fluorescence imagines were obtained using a Nikon
fluorescence microscope equipped with a rhodamine filter. The fluo-
rescence intensity values were calculated from three different wells
using a fluorescence spectrophotometer, and the average values were
represented.
Terminal Deoxynucleotidyl Transferase dUTP Nick-End
Labeling. Cell death in the myocardium was detected with the use
of terminal deoxynucleotidyl transferase dUTP nick-end labeling
(TUNEL) technique by using the Cardio TACS in situ apoptosis
detection kit (R&D Systems, Minneapolis, MN) according to the
manufacturer’s instruction. In brief, sections were incubated with
proteinase K for 20 min at room temperature and then washed with
phosphate-buffered saline. Endogenous peroxidase was inactivated
by 3% H2O2 for 5 min at room temperature, and sections were
incubated with labeling buffer containing terminal deoxynucleotidyl
transferase (TdT), Mn2, and biotinylated-deoxyuridine 5-triphos-
phate at 37°C for 60 min. Sections were then incubated with strepta-
vidin-horseradish peroxidase for 10 min, and the signals were visu-
alized with TACS blue. Quantitative analysis was performed by
using the Metamorph Series 6.2 image analysis program. The per-
centage of TUNEL-positive cells was calculated as a percentage of
total cells viewed in five randomly selected fields for each animal,
and three animals were studied per group.
Reverse Transcriptase-Polymerase Chain Reaction. Expres-
sion of FasL and several proinflammatory cytokines, including TNF-,
IL-1, IL-6, and iNOS in themyocardium, were examined using reverse
transcriptase (RT)-polymerase chain reaction (PCR). Total RNA was
extracted from frozen cardiac tissues obtained from WT and sFas mice
using TRIzol Reagent (Invitrogen, Carlsbad, CA) according to the man-
ufacturer’s instructions. RNA quantity was monitored at 260 nm. Total
RNA (2 g) was reverse transcribed to cDNA using the SuperScript
First-Strand Synthesis System (Bio-Rad-IScript; Bio-Rad, Hercules,
CA). Subsequently, the resulting cDNA was amplified with the follow-
ing primers for detecting FasL, TNF-, IL-1, IL-6, and iNOS genes
expression. Primer pairs used were as follows: FasL: forward, 5	-GCC-
CATGAATTACCCATGTG-3	 and reverse, 5	-GCCAGAGATTTGTGTT-
GTGG-3	; TNF-: forward 5	-ACTCAACAAACTGCCCTTCTGAG-3	
and reverse, 5	-TTACAGCTGGTTTCGATCCATTT-3	; IL-1: forward,
5	-TGTGGCTGTGGAGAAGCTGT-3	 and reverse, 5	-CAGCTCATAT-
GGGTCCGAGA-3	; IL-6: forward, 5	-CACGGCCTTCCCTACTTCAC-3	
and reverse, 5	-TGCAAGTGCATCATCGTTGT-3	; and iNOS: for-
ward, 5	-ACATCGACCCGTCCACAGTAT-3	 and reverse, 5	-CAG-
AGGGGTAGGCTTGTCTC-3	. Likewise, -actin primers (forward,
5	-AAATCGTGCGTGACATCAAAG-3	 and reverse, 5	-TGTAGTTTC-
ATGGATGCCACAG-3	) were used in PCR reactions under the same
conditions, which included an initial denaturation (94°C/5 min), fol-
lowed by a cycle of denaturation (94°C/30 s), annealing (60°C/30 s), and
extension (72°C/30 s). Each sample was subjected to 35 cycles followed
by a final extension (72°C/10 min). PCR products were separated and
visualized on 1.5% agarose ethidium bromide-stained gel. Band inten-
sity was assessed using imaging software (Alphaimager 2200). The
transcript levels of FasL, TNF-, IL-1, IL-6, and iNOS were normal-
ized to -actin in each sample and expressed as the ratio of expression
of -actin.
Measurement of Serum Nitrite and Nitrate.Whole blood was
collected from Dox- and saline-treated WT and sFas mice on the day
that animals were euthanized. Circulating levels of nitrite and ni-
trate, the major metabolites of nitric oxide (NO), were measured by
Griess reagent kit (Invitrogen) according to the manufacturer’s in-
structions. The absorbance at 550 nm was then measured using
microplate reader, and the levels of nitrite and nitrate were deter-
mined from standard curves.
Data and Statistical Analysis. All values are presented as
mean 
 S.E.M. of n observations; n represents the number of ani-
mals studied. The results were analyzed by one-way analysis of
variance (ANOVA) followed by a post-test for multiple comparisons.
A p value of less than 0.05 was considered significant.
Results
Clinical Manifestations in Mice after Dox Treat-
ment. As reported by others (Sun et al., 2001), during the
course of Dox treatment, a significant inhibition of body
weight gain in WT mice has been noted after 6 weeks of
injections compared with the saline-treated controls,
whereas this Dox-induced inhibition of body weight gain was
suppressed in sFas mice (data not shown). WT animals also
showed signs of heart failure-like syndrome including leth-
argy, ruffled hair, and respiratory stress at week 9, and
pleural effusions began to appear in five of 12 Dox-treated
WT animals at week 10, and three of 12 Dox-treated WT
animals died spontaneously at week 11 after first Dox ad-
ministration. In contrast, sFas animals remained healthy at
this time point. Gross anatomical examinations at the end of
study period showed that the hearts were dilated in both the
atrium and the ventricle, especially in the left atrium, in the
Dox-treated WT mice (Fig. 1A). The heart/body weight ratio
was markedly increased in the Dox-treated WT mice but not
in the sFas transgenic mice (Fig. 1B).
Histological Changes. Histological examination showed
that, in comparison with the saline-treated controls (Fig. 2, A
and B), the myocardium from Dox-treated WT mice showed
myocardial fiber swelling and diffuse myocyte vasculariza-
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Fig. 1. Targeted cardiac expression of sFas protects against Dox-induced
cardiomyopathy. A, gross anatomical inspection reveals marked cardio-
megaly in Dox-treated WT heart (left) compared with Dox-treated sFas
heart (right). B, quantitative data for heart weight index of the saline-
and Dox-treated WT and sFas mice. White bars, saline injection; shaded
bars, Dox injection. , p  0.05 versus saline-injected WT mice and
Dox-treated sFas mice; n  10 to 12 per group.
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tion (Fig. 2C), whereas these histological degenerative
changes were barely found in Dox-treated sFas mice (Fig.
2D). Cardiac sections were stained with Masson’s trichrome
for detection of collagen deposition (Fig. 2, E and F), and
myocardial interstitial fibrosis was determined by measure-
ment of collagen volume fraction. WT animals treated with
Dox demonstrated increased collagen volume fraction (2.4 

0.16%), which was much less in Dox-treated sFas animals
(0.52 
 0.09%, p  0.05). There was no difference in the
collagen volume fraction between saline-treated WT and
sFas mice (0.48 
 0.07 versus 0.46 
 0.09%, p  0.05).
sFas Transgenic Mice Are Resistant to Dox-Induced
Cardiac Dysfunction. At the starting of the Dox adminis-
tration, all the experimental animals showed the same of left
ventricular dimension and the percentage of fraction short-
ening, and there were no differences in these parameters
between saline-treated WT and sFas mice (data not shown).
Shown in Fig. 3A are representative two-dimensional M-
mode tracings of LV wall motion from a WT and a sFas
animal at baseline and after Dox treatment, respectively. In
contrast to the LV wall motion at baseline, the waveforms
from the Dox-treated animal clearly demonstrated blunted
anterior and posterior wall motion, consistent with decreased
fractional shortening (p  0.05; Fig. 3B), indicating a de-
crease in myocardial contractility in WTmice after Dox treat-
ment. In contrast, fractional shortening from the Dox-treated
sFas mice showed a slight decrease but was comparable with
that of baseline (Fig. 3B). In contrast to the LV end-diastolic
dimension at baseline, Dox treatment induced a slight in-
crease but did not result in significant change in LV end-
diastolic dimension in both WT and sFas mice (Fig. 3C).
These results indicate that mice with cardiac-specific expres-
sion of sFas seem to be resistant to Dox-induced cardiac
dysfunction.
Dox-Mediated Induction of FasL Is Reduced in sFas
Mice. Dox has been shown recently to activate FasL tran-
scription via the nuclear factor of activated T-lymphocytes
(NFAT) signaling mechanism in vitro (Kalivendi et al., 2005).
We examined whether FasL was induced after Dox adminis-
tration in vivo. RT-PCR analysis was performed to assess
FasL mRNA levels in cardiac tissue of WT and sFas mice
treated with saline or Dox. As demonstrated in Fig. 4, FasL
mRNA levels are significantly induced in Dox-treated WT
animals in comparison with saline-treated controls, whereas
sFas mice showed less levels of FasL mRNA transcript in
comparison with those in WT mice after Dox administration.
Dox-Induced Cell Death in the Myocardium Is Atten-
uated by Expression of sFas. Administration of Dox sig-
nificantly increased the number of TUNEL-positive cells in
the myocardium of WT mice (Fig, 5A), whereas only a few of
the apoptotic cells were present in the myocardium of Dox-
treated sFas mice (Fig. 5B). Quantification of TUNEL-posi-
tive cells in the myocardium demonstrated that the number
of apoptotic cells was significantly reduced in the myocar-
dium of Dox-treated sFas mice compared with Dox-treated
WT animals (Fig. 5E). In hearts from saline-treated mice,
there were only a few apoptotic cells observed in the myocar-
dium of both WT and sFas mice (data not shown).
The proapoptotic signal triggered by FasL is very rapidly
propagated through sequential activation of caspases that
result in cleavage of PARP into two fragments, i.e., p85 and
p25. Detection of caspase-3 cleavage fragments of PARP has
been established as a hallmark of apoptosis (Duriez and
Shah, 1997). We observed a significant increase in PARP p85
fragment-positive cells after Dox administration in the myo-
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Fig. 3. Echocardiographic analysis of cardiac function of mice treated
with Dox administration. A, representative two-dimensional M-mode
tracings of LV wall motion in WT and sFas mice given Dox. B, fractional
shortening normalized to the baseline measurements in WT mice show-
ing progressively declined after Dox injection, whereas no significant
effects were observed in Dox-treated sFas mice. C, LVEDDs did not
significantly change in the two groups after Dox treatment. , p  0.05
versus baseline; #, p  0.05 versus Dox-treated sFas mice; n  5 per
group.
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Fig. 2. Representative photomicrographs demonstrating the effect of
cardiac-specific expression of sFas on Dox-induced cardiac histopathol-
ogy. A to D, hematoxylin and eosin-stained sections of paraffin-embedded
hearts reveals prominent and diffuse vascularization in the Dox-treated
WT mice (C) but not saline control (A and B) and Dox-treated (D) sFas
mice. E and F, Masson’s trichrome-stained sections showing interstitial
fibrosis (blue) in Dox-treated WT (E) but not Dox-treated sFas mice (F).
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cardium of WT mice (Fig. 5, C and F). This increase was
significantly reduced in the myocardium of sFas mice (Fig. 5,
D and F). Therefore, these data indicate that myocardial
histological damage induced by Dox is significantly attenu-
ated by targeted cardiac-specific expression of sFas.
Expression of sFas Ameliorated Dox-Induced Car-
diac Oxidative-Nitrosative Stress. Previous work sug-
gested that Dox cardiotoxicity involved the increased forma-
tion of NO, superoxide, and, therefore, peroxynitrite,
enhancing oxidative-nitrosative stress to the heart (Wein-
stein et al., 2000; Chaiswing et al., 2004; Andreadou et al.,
2007). Therefore, superoxide generation in the hearts of each
group was estimated as an indicator of tissue oxidative
stress. As shown in Fig. 6A, the myocardial superoxide con-
tents were similar in saline-treated WT and sFas mice. In
contrast, there was a marked elevation of superoxide gener-
ation in WT hearts treated with Dox, and this elevation was
significantly inhibited by cardiac-targeted expression of
sFas. To determine the effect of sFas on the generation of
intracellular reactive oxygen species, the H9c2 cells were
pretreated with 10 g of sFas and incubated with 2 M Dox
for 6 h. We used the fluorescent probe, dihydroethidium,
which has been used to detect intracellular superoxide for-
mation (Benov et al., 1998). Figure 6B shows the intracellu-
lar red fluorescence because of the intercalation of ethidium
into DNA. Dox-induced enhancement in ethidium fluores-
cence was inhibited by the presence of sFas (Fig. 6C), indi-
cating an overall reduced oxidative stress.
Peroxynitrite, a potent oxidant and nitrating intermediate,
is a product of the reaction of superoxide and NO derived
from iNOS. To evaluate the possible involvement of nitrosa-
tive damage in the pathogenesis of the cardiomyopathy after
Dox treatment and the effect of cardiac-targeted expression
of sFas on this process, we performed immunohistochemistry
to examine the production of peroxynitrite by detecting ni-
trotyrosine residues in proteins with the 3-NT antibody. As
shown in Fig. 7A, 3-NT levels were highly elevated in the
myocardium of Dox-treatedWTmice compared with the myo-
cardium of the Dox-treated sFas mice, where only a very
weak signal of 3-NT could be detected. There was no positive
staining of 3-NT in the myocardium of both saline-treated
WT and sFas mice. Quantification of the 3-NT staining re-
vealed a drastic reduction in nitrotyrosine formation in the
myocardium of the Dox-treated sFas mice compared with
Dox-treated WT mice (Fig. 7B).
To elucidate the changes of iNOS expression in the hearts
of each group, total cardiac RNA was subjected to RT-PCR for
mouse-specific iNOS and -actin as a control. Cardiac iNOS
mRNA was significantly increased in the myocardium of WT
mice after Dox treatment in comparison with saline-treated
controls, whereas this increase in iNOS expression was sig-
nificantly suppressed in the myocardium of Dox-treated sFas
mice (Fig. 7C). Nitrate and nitrite analysis of the plasma
showed that the levels of nitrate and nitrite after Dox treat-
ment were significantly less in sFas mice than the levels
found in WT mice, although the magnitude of the reduction
in sera levels of nitrate and nitrite did not reach exactly the
levels observed in saline-treated controls (Fig. 7D). Together,
these results indicate that the neutralization of FasL by
cardiac-specific expression of sFas attenuated Dox-induced
cardiac oxidative-nitrosative stress.
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Fig. 5. Dox-induced cell death in the myocardium is attenuated by ex-
pression of sFas. A and B, representative photomicrographs of TUNEL-
stained sections obtained from Dox-treated WT mice and Dox-treated
sFas mice. Blue staining, TUNEL-positive cells. C and D, representative
photomicrographs of immunohistochemical staining demonstrated a
strong immunoreactivity for PARP p85 fragment in the myocardial sec-
tions from Dox-treated WT mice compared with very little immunoreac-
tivity in the myocardium of Dox-treated sFas mice. Immunoreactivity
was visualized with diaminobenzidine (brown). E and F, histograms
showing a marked decrease in TUNEL-positive cells and PARP p85
fragment immunoreactivity, respectively, in the myocardium of Dox-
treated sFas mice compared with Dox-treated WT mice. n  5 per group;
, p  0.01 versus saline-treated WT and sFas mice; #, p  0.05 versus
Dox-treated sFas mice.
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Fig. 4. Dox-mediated induction of FasL is attenuated in sFas transgenic
mice. A, FasL mRNA in the myocardium of saline- and Dox-treated WT
and sFas mice were assayed by RT-PCR. B, RT-PCR data were quanti-
tated by densitometric analysis and normalized against -actin. n 5 per
group; , p  0.01 versus saline-treated WT and sFas mice; #, p  0.05
versus Dox-treated sFas mice.
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Dox-Mediated Induction of Cytokines is Suppressed
by Expression of sFas. Cytokines, such as TNF-, IL-1, and
Il-6, have been shown to be involved in different cardiac dis-
eases and heart failure (Mann, 2002). To assess whether these
cytokines were induced after Dox administration, we performed
RT-PCR analysis to evaluate TNF-, IL-1, and IL-6 mRNA
levels in cardiac tissue of Dox-treated WT and sFas mice and
saline-treated controls. As shown in Fig. 8, TNF-, IL-1, and
IL-6 mRNA levels are significantly elevated in the myocardium
of WT mice after Dox administration in comparison with those
of the saline-treated controls. The mRNA levels of TNF-, IL-
1, and IL-6 in the Dox-treated sFas mice were significantly
lower in comparison with those of Dox-treated WT mice, sug-
gesting that the induction of these cytokines caused by Dox
treatment involved Fas/FasL signaling.
Discussion
Cardiac toxicity is a major dose-limiting factor for applica-
tion of doxorubicin as a cancer chemotherapeutic agent. Al-
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Fig. 7. DOX-induced nitrotyrosine formation
and iNOS expression in heart are attenuated
by cardiac-specific expression of sFas. A, rep-
resentative photomicrographs of immuno-
histochemical staining revealed a strong im-
munoreactivity for 3-NT in the myocardial
section obtained from Dox-treated WT mice
compared with less immunoreactivity in the
myocardial section from Dox-treated sFas
mice. Immunoreactivity was visualized with
diaminobenzidine (brown). There was no pos-
itive staining for 3-NT in myocardial sections
from saline-treated controls. B, histogram
showing a significant decrease of the immu-
noreactivity for nitrotyrosine in the myocar-
dium of Dox-treated sFas mice compared
with Dox-treated WT mice. #, p  0.01, n  5
per group. C, iNOS mRNA expression in the
myocardium of saline-, Dox-treated WT and
sFas mice were assayed by RT-PCR, and the
bands of iNOS expression were quantitated
by densitometric analysis and normalized by
-actin. n  5 per group; , p  0.01 versus
saline-treated WT and sFas mice; #, p  0.05
versus Dox-treated WT mice. D, circulating
levels of nitrite and nitrate, in saline-, Dox-
treated WT and sFas mice. Total nitrated
proteins significantly increased in the serum
of Dox-treated WT mice compared with the
saline-treated controls and Dox-treated sFas
mice. , p  0.01 versus saline-treated con-
trols; #, p  0.05 versus Dox-treated WT
mice; n  5 per group.
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Fig. 6. Dox-induced generation of ROS is inhib-
ited by cardiac-specific expression of sFas. A,
Dox-induced superoxide generation in myocar-
dial homogenates was determined by luminol-
mediated chemiluminescence assay after addi-
tion of 200 ng/ml PMA. Superoxide production
was expressed as the light intensity per milli-
gram of protein. , p 0.01 versus saline-treated
WT and sFas controls; #, p  0.05 versus Dox-
treated WT mice; n  3 per group. B and C, sFas
inhibited Dox-induced oxidative stress as mea-
sured by DHE fluorescence. H9c2 cells treated
with Dox (2 M) with or without sFas (10 g/ml)
as described underMaterials and Methods. After
6 h of incubation, the medium was aspirated,
and cells were washed with Dulbecco’s phos-
phate-buffered saline and incubated with 10 M
DHE for 30min. Representativemicrophotographs
of differential interference contrast (DIC) images
and DHE-stained images are shown in B. The red
fluorescence indicates positive staining. C, inten-
sity of fluorescence was measured by a fluores-
cence spectrophotometer and averaged from three
samples for each group. , p  0.01 versus un-
treated control; #, p  0.05 versus Dox-treated
cells.
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though the precise biochemical mechanisms of Dox cardio-
toxicity remain uncertain, it has been demonstrated that the
cardiac toxicity associated with Dox administration is medi-
ated, at least in part, by induction of oxidative stress (Wein-
stein et al., 2000; Chaiswing et al., 2004; Andreadou et al.,
2007) and cardiac cell apoptosis (Kalyanaraman et al., 2002;
Takemura and Fujiwara, 2007). In a recent study, in vitro
experiments demonstrated that ROS generated from Dox
metabolism in mitochondrial activates NFAT signaling,
which leads to the initiation of the apoptotic cascade in car-
diac cells with FasL transcription (Kalivendi et al., 2005). In
the present study, we demonstrated that expression and
secretion of sFas by the myocardium to decoy of FasL results
in lower production of proinflammatory cytokines, fewer
TUNEL-positive cells, and less formation of superoxide and
peroxynitrite in the myocardium, leading to preserved car-
diac function in the experimental mouse model of Dox car-
diotoxicity. This study provides direct in vivo evidence for the
involvement of Fas/FasL signaling in Dox cardiotoxicity.
Dox-induced cardiotoxicity has been attributed, at least in
part, to cardiac cell apoptosis (Kalyanaraman et al., 2002;
Takemura and Fujiwara, 2007). FasL is a well characterized
apoptosis inducer that binds to its cell surface receptor Fas,
resulting in sequential activation of caspases, forming the
death-inducing signaling complex that triggers apoptosis
(Suda et al., 1993). Previous studies have demonstrated a
dose-related increase in the expression of Fas antigen and
cardiac myocyte and endothelial cell apoptosis with Dox
treatment (Nakamura et al., 2000; Lien et al., 2006). For our
investigation, a cumulative Dox dose of 40 mg/kg was given
to the mice over 7 weeks. The animals showed heart failure-
like syndrome, including lethargy, ruffled hair, respiratory
stress, and pleural effusions. To confirm the presence of
apoptosis, we measured cell death using the TUNEL assay
and immunohistochemistry. Large numbers of TUNEL-pos-
itive cells were found in the myocardium of Dox-treated WT
mice, whereas fewer TUNEL-positive cells were observed in
the myocardium of Dox-treated sFas mice. The TUNEL-pos-
itive cells were cardiomyocytes, endothelial cells, and infil-
trating inflammatory cells that were consistent with the
findings of previous in vivo studies (Nakamura et al., 2000;
Wu et al., 2002). To further assess a link between the induc-
tion of apoptosis and caspase-3-activated PARP cleavage, we
performed immunostaining of myocardial sections using an-
tibody against the p85 fragment of PARP. The appearance of
the 85-kDa fragment of PARP in the cardiomyocyte nuclei
coincided with a significant increase of TUNEL-positive cells
in the myocardium of Dox-treated WT mice. In contrast,
fewer positive cells were observed in the myocardial sections
obtained from Dox-treated sFas mice. This observation is in
concordance with our recent data showing sFas inhibition of
caspase-3/7 activities and activation of PARP in the myocar-
dium (Niu et al., 2008). These data together indicate that
sFas expression protects against Dox-induced cardiac dys-
function, at least in part by preventing apoptotic cell death of
cardiac cells, further supporting the important role of FasL
expression in Dox cardiotoxicity.
Dox-induced cardiac cell apoptosis has been attributed to
the production of ROS (Chaiswing et al., 2004), which has
been shown to activate FasL transcription (Kalivendi et al.,
2005). Activation of the Fas receptor has been shown to be
associated with rapid generation of ROS (Gulbins et al.,
1996; Sato et al., 2004; Medan et al., 2005). The generation of
ROS such as peroxynitrite, the reaction product of NO and
superoxide, has been implicated in the pathogenesis of Dox-
induced myocardial dysfunction (Weinstein et al., 2000;
Chaiswing et al., 2004; Andreadou et al., 2007). Although
studies suggest that NO by itself is an antioxidant molecule
(Wink et al., 1993), increased NO production via iNOS has
been implicated in cardiomyocyte oxidative damage, apopto-
sis, and/or necrosis through peroxynitrite formation (Ferdi-
nandy et al., 2000; Zhang et al., 2007; Niu et al., 2008).
Peroxynitrite-related cardiac protein nitration, myofibrillar
thinning, and irregular striations patterns have been docu-
mented to be responsible for cardiac dysfunction in doxoru-
bicin-treated mice (Mihm et al., 2002). Our results showed
that superoxide generation in the heart was greatly en-
hanced after Dox treatment. This was confirmed in cultured
H9c2 cells in vitro by measurement of intracellular reactive
species using fluorescence probe dihydroethidium. We also
found increased iNOS expression, elevation of nitrite and
nitrate, and formation of peroxynitrite in WT mice after Dox
treatment. These findings are in accordance with the previ-
ous reports that NO-derived oxidative species and particu-
larly peroxynitrite are formed during Dox induced cardio-
toxicity (Weinstein et al., 2000; Chaiswing et al., 2004;
Andreadou et al., 2007). In contrast, these changes were
inhibited by neutralization of FasL through cardiac-targeted
expression of sFas, resulting in protection of the heart
against the toxic effect of Dox. This suggests that neutraliza-
tion of FasL by cardiac-targeted expression of sFas decreased
the levels of Dox-induced cardiac oxidative stress. Our find-
ings are supported by recent studies showing that FasL in-
duces ROS generation by activation of NADPH oxidase
(Wang et al., 2008). Thus, we present the first in vivo evi-
dence that FasL is an important mediator in Dox-associated
Fig. 8. Cardiac-specific expression of sFas suppresses myocardial proin-
flammatory cytokine production after Dox treatment. A, expression of
TNF-, IL-1, and IL-6 mRNA in the myocardium of saline-, Dox-treated
WT and sFas mice were assayed by RT-PCR. B to D, RT-PCR Bands were
quantitated by densitometric analysis and normalized by -actin. n  5
per group; , p  0.05 versus saline-treated controls; #, p  0.05 versus
Dox-treated sFas mice.
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cardiotoxicity by generating reactive oxygen and nitrogen
species.
Increased iNOS expression and nitrotyrosine formation
have been observed in mice cardiomyocytes after Dox treat-
ment (Mihm et al., 2002). Higher NO production via iNOS
has been shown to be associated with the pathogenesis of
cardiomyopathy and heart failure. However, the concept that
deficiency of iNOS may enhance Dox-induced acute cardio-
toxicity in mice was also documented recently (Cole et al.,
2006). We did detect an increase in iNOS mRNA and nitro-
tyrosine formation in the hearts of WT mice treated with
Dox, and these increases in iNOS expression, NO production,
superoxide generation, and nitrotyrosine formation were ac-
companied by a marked loss of cardiac mechanical function,
whereas these changes were attenuated in sFas mice with
preservation of cardiac function. In the presence of Dox, not
only NO synthesis is elevated, but also the generation of
myocardial superoxide. Superoxide can react with NO to
reduce its bioavailability, leading to formation of peroxyni-
trite, a highly toxic reactive species. Based on our data, it
seems likely that elevated NO and reactive oxygen species
production would contribute to chronic Dox cardiotoxicity,
suggesting that inhibition of production of either of the per-
oxynitrite precursors (NO or superoxide) would have a ben-
eficial effect on myocardial oxidative stress and contractile
function.
Although Fas is best known for its involvement in the
regulation of apoptosis, Fas ligation also contributes to acti-
vation of NF-B (Ponton et al., 1996), and it has been shown
that interruption of Fas/FasL signaling suppressed NF-B
activation and cytokine expression (Shiraishi et al., 2002).
We recently showed that NF-B activation and production of
proinflammatory cytokines were suppressed in sFas trans-
genic mice (Niu et al., 2008). A recent study has reported that
NF-B activation is necessary for cardiomyocyte apoptosis
evoked by Dox (Wang et al., 2002). In the present study, we
found that Dox administration leads to a substantial increase
in the levels of TNF-a, IL-1, and IL-6 in the myocardial
tissues of WT animals after Dox administration. In contrast,
the levels of these proinflammatory cytokines were signifi-
cantly lower in the myocardial tissues of Dox-treated sFas
animals. Although there is increasing evidence that short-
term expression of proinflammatory cytokines, such as
TNF-, can be beneficial to the heart (Wilson et al., 2004),
our data demonstrated that increases in proinflammatory
cytokine production are accompanied by a marked loss of
cardiac mechanical function in chronic Dox cardiotoxicity.
Taken together, these results suggest that not only the direct
effect of oxidative stress but also the inflammatory response
induced by FasL plays a significant role in Dox-associated
cardiotoxicity. Because iNOS expression is induced upon cy-
tokine stimulation (Zeng et al., 2005), the inhibition of NF-B
activation and proinflammatory cytokine production by neu-
tralization of FasL may explain the decreased levels of NO in
sFas mice. In agreement with this finding, it has been re-
ported that impairment of the Fas-FasL interaction resulted
in decreased NO production (Martins et al., 2001). In this
study, we also examined FasL gene expression, and there
was a substantial decrease of FasL transcript in the hearts of
sFas mice compared with WT mice after Dox treatment. The
mechanism(s) responsible for suppression of FasL expression
in sFas mice is not clear. It is likely that reduced ROS
generation and inactivation of NF-B may attenuate Dox-
induced activation of NFAT signaling mechanism, resulting
in decreased FasL expression in the hearts of sFas animals.
In conclusion, the present study clearly demonstrates that
sFas-induced protective effect against Dox-induced cardiac
toxicity in mice is attributable to attenuation of ROS gener-
ation, peroxynitrite formation, inhibition of myocyte apopto-
sis, and reduction of proinflammatory cytokine production.
These findings demonstrate that FasL is a key mediator of
Dox-induced cardiac toxicity and, therefore, may provide a
novel therapeutic strategy in clinic to reduce Dox-induced
cardiotoxicity in patients.
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